Physician
The Regional Medical Center of Orangeburg and Calhoun Counties
The Regional Medical Center of Orangeburg and Calhoun Counties was paid $25.67M by Medicaid between Jan 2018 and Feb 2023, across 350 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 16% of everything it billed.
33Billing provider infoTHE REGIONAL MEDICAL CENTER OF ORANGEBURG AND CALHOUN COUNTIES
ORANGEBURG, SC 29118
ORANGEBURG, SC 29118
33aNPI1457309247assigned 05/04/2006
33bProvider typeEmergency Medicine Physician
28Total paid$25.67M
24GClaims1,239,254
24DCodes billed350
24AFirst – last monthJan 2018 – Feb 2023
Compared with peers
Next to other Emergency Medicine Physician providers in South Carolina
Rank by total paid#1 of 263
Median peer was paid$3K
This provider vs. median8,467×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 228,161 | $4.42M | |
| 2019 | 267,553 | $5.26M | |
| 2020 | 222,711 | $4.15M | |
| 2021 | 218,100 | $4.99M | |
| 2022 | 259,672 | $6.01M | |
| 2023 | 43,057 | $848K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 16% | 68,898 | 44,492 | $4.18M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.0% | 48,985 | 43,447 | $1.54M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 5.5% | 20,435 | 12,728 | $1.41M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 5.4% | 12,832 | 10,541 | $1.39M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.5% | 77,571 | 53,300 | $1.15M |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 4.4% | 7,933 | 4,528 | $1.12M |
| 81001 | 3.9% | 43,089 | 36,235 | $1.01M | |
| 87070 | 3.6% | 11,473 | 10,767 | $937K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 14,488 | 13,381 | $666K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.5% | 6,795 | 5,886 | $637K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.3% | 2,628 | 2,287 | $591K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.1% | 41,130 | 35,319 | $551K |
338 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 6,459 | $510K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 19,262 | $454K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.6% | 25,327 | $411K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 12,147 | $408K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 6,229 | $373K |
| 84703 | 1.5% | 19,014 | $373K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 1.3% | 1,437 | $346K |
| 87430 | 1.2% | 13,723 | $297K | |
| 36592 | 1.0% | 11,113 | $262K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,456 | $244K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,899 | $210K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,259 | $193K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,182 | $173K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 8,412 | $172K |
| 93970 | <1% | 1,367 | $165K | |
| 85730 | <1% | 13,917 | $162K | |
| 73610 | <1% | 2,119 | $156K | |
| 93971 | <1% | 1,652 | $154K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 6,671 | $151K |
| 73630 | <1% | 2,593 | $148K | |
| 86756 | <1% | 1,789 | $140K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 31,090 | $132K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,923 | $130K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,864 | $126K |
| 73560 | <1% | 2,612 | $123K | |
| 99285 | Emergency room visit (most serious) | <1% | 16,914 | $120K |
| 73130 | <1% | 1,627 | $115K | |
| 85027 | <1% | 1,580 | $111K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,341 | $110K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,885 | $103K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,500 | $102K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,423 | $101K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,506 | $101K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,553 | $99K |
| 86901 | <1% | 3,306 | $98K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,524 | $91K |
| 80053 | Comprehensive metabolic panel | <1% | 58,825 | $91K |
| 99152 | <1% | 338 | $91K | |
| 96376 | <1% | 6,047 | $90K | |
| 82565 | <1% | 956 | $86K | |
| 73110 | <1% | 1,154 | $85K | |
| 10060 | <1% | 531 | $83K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,289 | $81K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,329 | $79K |
| 73030 | <1% | 2,101 | $78K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,237 | $77K |
| 36000 | <1% | 2,125 | $73K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,988 | $69K |
| 88342 | <1% | 295 | $68K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,652 | $66K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 3,128 | $62K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,168 | $59K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,354 | $58K |
| 73140 | <1% | 494 | $57K | |
| 72100 | <1% | 2,173 | $55K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 15,820 | $53K |
| 87077 | <1% | 4,330 | $50K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 713 | $49K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,071 | $49K |
| 74018 | <1% | 1,299 | $48K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,981 | $46K |
| 85610 | <1% | 16,269 | $44K | |
| 72040 | <1% | 858 | $43K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,331 | $43K |
| 93017 | <1% | 1,733 | $42K | |
| 12001 | <1% | 491 | $40K | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 55 | $40K |
| 96377 | <1% | 134 | $39K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,116 | $38K |
| 36589 | <1% | 531 | $37K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 537 | $35K |
| 87653 | <1% | 797 | $35K | |
| 96367 | <1% | 1,952 | $35K | |
| G0378 | Hospital observation service, per hour | <1% | 9,581 | $34K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,246 | $34K |
| 73502 | <1% | 1,284 | $33K | |
| A9270 | Non-covered item or service | <1% | 59,379 | $28K |
| 73590 | <1% | 728 | $27K | |
| 80047 | <1% | 5,548 | $26K | |
| 70486 | <1% | 667 | $26K | |
| 76801 | <1% | 1,521 | $25K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 96 | $25K |
| 87210 | <1% | 2,367 | $24K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,456 | $24K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 755 | $22K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 267 | $21K |
| 73562 | <1% | 536 | $21K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,308 | $21K |
| 97161 | <1% | 1,947 | $20K | |
| 73090 | <1% | 418 | $20K | |
| 85378 | <1% | 2,698 | $19K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 103 | $19K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 604 | $18K |
| 99153 | Mod sedat endo service >5yrs | <1% | 621 | $17K |
| 96417 | <1% | 618 | $16K | |
| 82550 | <1% | 3,678 | $16K | |
| C1780 | Lens, intraocular (new technology) | <1% | 713 | $15K |
| 12011 | <1% | 134 | $15K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,691 | $15K |
| 71250 | <1% | 445 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 739 | $14K |
| 95811 | <1% | 63 | $13K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 7,170 | $13K |
| 73080 | <1% | 275 | $13K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 9,216 | $12K |
| 77336 | <1% | 97 | $12K | |
| 87340 | <1% | 356 | $12K | |
| 88304 | <1% | 403 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,325 | $12K |
| 93990 | <1% | 1,335 | $12K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,294 | $11K |
| 76642 | <1% | 300 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 10,935 | $10K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,588 | $10K |
| 93880 | <1% | 123 | $10K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 69 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,937 | $9K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,904 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 277 | $9K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 199 | $9K |
| 86920 | <1% | 554 | $8K | |
| 84100 | <1% | 3,201 | $8K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 3,090 | $8K |
| 74022 | <1% | 709 | $8K | |
| 97116 | <1% | 1,012 | $8K | |
| 84702 | <1% | 3,166 | $8K | |
| 93923 | <1% | 47 | $8K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 74 | $8K |
| 87205 | <1% | 1,420 | $7K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 1,383 | $7K |
| 85045 | <1% | 1,421 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,750 | $6K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 78 | $6K |
| 36902 | <1% | 1,522 | $6K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 341 | $6K |
| 84439 | <1% | 6,442 | $6K | |
| 83880 | <1% | 10,902 | $6K | |
| 77065 | Tomosynthesis, mammo | <1% | 175 | $5K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 12 | $5K |
| 84153 | <1% | 631 | $5K | |
| 59025 | Fetal non-stress test | <1% | 29 | $5K |
| 80061 | Lipid panel | <1% | 4,508 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,670 | $4K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,812 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 426 | $4K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,465 | $4K |
| 97165 | <1% | 432 | $4K | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 329 | $4K |
| 73620 | <1% | 75 | $4K | |
| 87147 | <1% | 52 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,747 | $4K |
| 85018 | <1% | 1,090 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,151 | $4K |
| 82803 | <1% | 1,868 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,749 | $3K |
| 87186 | <1% | 4,305 | $3K | |
| 83735 | <1% | 7,943 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,662 | $3K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 814 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,226 | $3K |
| 71101 | <1% | 50 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 356 | $3K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,780 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 5,667 | $3K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,275 | $3K |
| 94644 | <1% | 425 | $3K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 836 | $3K |
| 84484 | <1% | 17,896 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,178 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,364 | $3K |
| 93925 | <1% | 16 | $2K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 522 | $2K |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 296 | $2K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 87 | $2K |
| 83690 | <1% | 12,999 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 16 | $2K |
| 93296 | <1% | 40 | $2K | |
| 73060 | <1% | 42 | $2K | |
| 12002 | <1% | 52 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 839 | $2K |
| 82607 | <1% | 2,445 | $2K | |
| 76770 | <1% | 45 | $2K | |
| 76536 | <1% | 40 | $2K | |
| C1750 | Catheter, hemodialysis/peritoneal, long-term | <1% | 842 | $2K |
| 80076 | <1% | 1,364 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 317 | $2K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 191 | $2K |
| 85014 | <1% | 705 | $2K | |
| 93225 | <1% | 12 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 596 | $2K |
| 80320 | <1% | 4,575 | $2K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $2K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 856 | $2K |
| 87040 | <1% | 3,787 | $2K | |
| 80069 | <1% | 1,159 | $2K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 5,352 | $1K |
| 82728 | <1% | 3,790 | $1K | |
| 73660 | <1% | 13 | $1K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,043 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,843 | $1K |
| 86140 | <1% | 381 | $1K | |
| 76937 | <1% | 369 | $1K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 898 | $1K |
| 90715 | <1% | 1,168 | $1K | |
| 82570 | <1% | 951 | $1K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 51 | $1K |
| C1769 | Guide wire | <1% | 4,972 | $1K |
| 82248 | <1% | 582 | $1K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 887 | $1K |
| 83550 | <1% | 3,992 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,919 | $1K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 324 | $991.36 |
| 83605 | <1% | 3,170 | $991.30 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,342 | $967.04 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,337 | $928.92 |
| 83970 | <1% | 444 | $895.48 | |
| 97162 | <1% | 111 | $739.11 | |
| 73070 | <1% | 13 | $719.38 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 875 | $673.46 |
| 77080 | <1% | 13 | $673.14 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 124 | $665.84 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 80 | $638.88 |
| 72170 | <1% | 34 | $635.89 | |
| 82043 | <1% | 370 | $634.21 | |
| P9021 | Red blood cells, each unit | <1% | 341 | $633.64 |
| 85652 | <1% | 397 | $584.93 | |
| 86592 | <1% | 205 | $577.74 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 3,605 | $574.25 |
| 73552 | <1% | 26 | $567.70 | |
| 84550 | <1% | 849 | $567.36 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 718 | $479.57 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 600 | $455.43 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,859 | $447.70 |
| 80329 | <1% | 4,491 | $443.29 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,348 | $420.23 |
| 84403 | <1% | 12 | $399.54 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 193 | $345.80 |
| 99292 | <1% | 110 | $345.80 | |
| 84156 | <1% | 428 | $332.38 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 514 | $325.50 |
| 77001 | <1% | 664 | $321.05 | |
| 93985 | <1% | 147 | $273.52 | |
| 96523 | <1% | 13 | $264.60 | |
| C1788 | Port, indwelling (implantable) | <1% | 124 | $256.52 |
| 82947 | <1% | 623 | $211.00 | |
| 86850 | <1% | 2,074 | $187.14 | |
| 97597 | <1% | 18 | $173.62 | |
| 72070 | <1% | 14 | $157.72 | |
| 80055 | <1% | 476 | $139.34 | |
| 82247 | <1% | 92 | $138.36 | |
| 72131 | <1% | 29 | $110.79 | |
| 83540 | <1% | 4,007 | $101.16 | |
| 74021 | <1% | 41 | $83.46 | |
| 86703 | <1% | 821 | $70.16 | |
| 80164 | <1% | 337 | $59.32 | |
| 80177 | <1% | 110 | $45.23 | |
| 82150 | <1% | 635 | $41.85 | |
| 82378 | <1% | 1,068 | $27.83 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,501 | $17.82 |
| 82950 | <1% | 953 | $15.70 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 144 | $15.24 |
| 36600 | <1% | 1,329 | $9.66 | |
| 82310 | <1% | 172 | $6.24 | |
| 87158 | <1% | 275 | $5.38 | |
| 86900 | <1% | 2,562 | $4.28 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 443 | $2.54 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 502 | $0.48 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 86 | $0.00 |
| C1874 | Stent, coated/covered, with delivery system | 0% | 568 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 1,095 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 3,982 | $0.00 |
| J1453 | Injection, fosaprepitant, 1 mg | 0% | 202 | $0.00 |
| 36905 | 0% | 703 | $0.00 | |
| 36906 | 0% | 30 | $0.00 | |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 1,421 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 452 | $0.00 |
| 82010 | 0% | 152 | $0.00 | |
| 88312 | 0% | 314 | $0.00 | |
| 51702 | 0% | 92 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 405 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 124 | $0.00 |
| 75774 | 0% | 92 | $0.00 | |
| 86038 | 0% | 44 | $0.00 | |
| 36901 | 0% | 210 | $0.00 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | 0% | 210 | $0.00 |
| 85049 | 0% | 50 | $0.00 | |
| G0390 | Trauma response team associated with hospital critical care service | 0% | 48 | $0.00 |
| 36830 | 0% | 185 | $0.00 | |
| 84145 | 0% | 28 | $0.00 | |
| 86334 | 0% | 27 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 179 | $0.00 |
| 85007 | 0% | 301 | $0.00 | |
| 84165 | 0% | 40 | $0.00 | |
| 86431 | 0% | 15 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 55 | $0.00 |
| 77062 | 0% | 16 | $0.00 | |
| 84460 | 0% | 14 | $0.00 | |
| 36558 | 0% | 83 | $0.00 | |
| 29125 | 0% | 16 | $0.00 | |
| 86235 | 0% | 29 | $0.00 | |
| 84481 | 0% | 13 | $0.00 | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 19 | $0.00 |
| 90714 | 0% | 13 | $0.00 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | 0% | 16 | $0.00 |
| 36005 | 0% | 14 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 1,517 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,705 | $0.00 |
| 83615 | 0% | 896 | $0.00 | |
| 85660 | 0% | 149 | $0.00 | |
| C1768 | Graft, vascular | 0% | 457 | $0.00 |
| 82746 | 0% | 2,149 | $0.00 | |
| 36430 | 0% | 408 | $0.00 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 755 | $0.00 |
| 97166 | 0% | 20 | $0.00 | |
| 87181 | 0% | 114 | $0.00 | |
| J2505 | Injection, pegfilgrastim, 6 mg | 0% | 127 | $0.00 |
| 86905 | 0% | 160 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 197 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 171 | $0.00 |
| 82951 | 0% | 26 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 61 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 80 | $0.00 |
| 75710 | 0% | 45 | $0.00 | |
| 96415 | 0% | 457 | $0.00 | |
| 86300 | 0% | 76 | $0.00 | |
| 82553 | 0% | 338 | $0.00 | |
| 36832 | 0% | 79 | $0.00 | |
| 36581 | 0% | 29 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 39 | $0.00 |
| 84238 | 0% | 190 | $0.00 | |
| J2997 | Injection, alteplase recombinant, 1 mg | 0% | 12 | $0.00 |
| 93930 | 0% | 39 | $0.00 | |
| 36821 | 0% | 43 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 21 | $0.00 |
| 82784 | 0% | 74 | $0.00 | |
| 86301 | 0% | 15 | $0.00 | |
| 86803 | 0% | 13 | $0.00 | |
| 86255 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPORTERFIELD, LIZA (CFO)
| Provider | Location | Paid |
|---|---|---|
| The Regional Medical Center of Orangeburg and Calhoun Counties | Orangeburg, SC | $299K |
| Edisto Regional Health Services INC. | Bamberg, SC | $244K |
| Edisto Regional Health Services INC. | Orangeburg, SC | $65K |
| Edisto Regional Health Services INC. | North, SC | $47K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.